Cargando…
Type of chemotherapy has substantial effects on the immune system in ovarian cancer
Chemotherapy induces a variety of immunological changes. Studying these effects can reveal opportunities for successful combining chemotherapy and immunotherapy. Immuno-chemotherapeutic combinations in ovarian cancer are currently not generating the anticipated positive effects. To date, only scatte...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022256/ https://www.ncbi.nlm.nih.gov/pubmed/33770618 http://dx.doi.org/10.1016/j.tranon.2021.101076 |
_version_ | 1783674902278045696 |
---|---|
author | Vankerckhoven, Ann Baert, Thaïs Riva, Matteo De Bruyn, Christine Thirion, Gitte Vandenbrande, Katja Ceusters, Jolien Vergote, Ignace Coosemans, An |
author_facet | Vankerckhoven, Ann Baert, Thaïs Riva, Matteo De Bruyn, Christine Thirion, Gitte Vandenbrande, Katja Ceusters, Jolien Vergote, Ignace Coosemans, An |
author_sort | Vankerckhoven, Ann |
collection | PubMed |
description | Chemotherapy induces a variety of immunological changes. Studying these effects can reveal opportunities for successful combining chemotherapy and immunotherapy. Immuno-chemotherapeutic combinations in ovarian cancer are currently not generating the anticipated positive effects. To date, only scattered and inconsistent information is available about the immune-induced changes by chemotherapy in ovarian cancer. In this study, we compared six common chemotherapeutics used in ovarian cancer patients (carboplatin, paclitaxel, pegylated liposomal doxorubicin, gemcitabine, carboplatin-paclitaxel and carboplatin-gemcitabine) and studied their effects on the immune system in an ovarian cancer mouse model. Mice received a single chemotherapy or vehicle injection 21 days after tumor inoculation with ID8-fluc cells. One week after therapy administration, we collected peritoneal washings for flow cytometry, serum for cytokine analysis with cytometric bead array and tumor biopsies for immunohistochemistry. Carboplatin-paclitaxel showed the most favorable profile with a decrease in immunosuppressive cells in the peritoneal cavity and an increase of interferon-gamma in serum. In contrast, carboplatin-gemcitabine seemed to promote a hostile immune environment with an increase in regulatory T-cells in tumor tissue and an increase of macrophage-inflammatory-protein-1-beta in the serum. |
format | Online Article Text |
id | pubmed-8022256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Neoplasia Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-80222562021-04-15 Type of chemotherapy has substantial effects on the immune system in ovarian cancer Vankerckhoven, Ann Baert, Thaïs Riva, Matteo De Bruyn, Christine Thirion, Gitte Vandenbrande, Katja Ceusters, Jolien Vergote, Ignace Coosemans, An Transl Oncol Original Research Chemotherapy induces a variety of immunological changes. Studying these effects can reveal opportunities for successful combining chemotherapy and immunotherapy. Immuno-chemotherapeutic combinations in ovarian cancer are currently not generating the anticipated positive effects. To date, only scattered and inconsistent information is available about the immune-induced changes by chemotherapy in ovarian cancer. In this study, we compared six common chemotherapeutics used in ovarian cancer patients (carboplatin, paclitaxel, pegylated liposomal doxorubicin, gemcitabine, carboplatin-paclitaxel and carboplatin-gemcitabine) and studied their effects on the immune system in an ovarian cancer mouse model. Mice received a single chemotherapy or vehicle injection 21 days after tumor inoculation with ID8-fluc cells. One week after therapy administration, we collected peritoneal washings for flow cytometry, serum for cytokine analysis with cytometric bead array and tumor biopsies for immunohistochemistry. Carboplatin-paclitaxel showed the most favorable profile with a decrease in immunosuppressive cells in the peritoneal cavity and an increase of interferon-gamma in serum. In contrast, carboplatin-gemcitabine seemed to promote a hostile immune environment with an increase in regulatory T-cells in tumor tissue and an increase of macrophage-inflammatory-protein-1-beta in the serum. Neoplasia Press 2021-03-23 /pmc/articles/PMC8022256/ /pubmed/33770618 http://dx.doi.org/10.1016/j.tranon.2021.101076 Text en © 2021 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Vankerckhoven, Ann Baert, Thaïs Riva, Matteo De Bruyn, Christine Thirion, Gitte Vandenbrande, Katja Ceusters, Jolien Vergote, Ignace Coosemans, An Type of chemotherapy has substantial effects on the immune system in ovarian cancer |
title | Type of chemotherapy has substantial effects on the immune system in ovarian cancer |
title_full | Type of chemotherapy has substantial effects on the immune system in ovarian cancer |
title_fullStr | Type of chemotherapy has substantial effects on the immune system in ovarian cancer |
title_full_unstemmed | Type of chemotherapy has substantial effects on the immune system in ovarian cancer |
title_short | Type of chemotherapy has substantial effects on the immune system in ovarian cancer |
title_sort | type of chemotherapy has substantial effects on the immune system in ovarian cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8022256/ https://www.ncbi.nlm.nih.gov/pubmed/33770618 http://dx.doi.org/10.1016/j.tranon.2021.101076 |
work_keys_str_mv | AT vankerckhovenann typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT baertthais typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT rivamatteo typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT debruynchristine typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT thiriongitte typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT vandenbrandekatja typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT ceustersjolien typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT vergoteignace typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer AT coosemansan typeofchemotherapyhassubstantialeffectsontheimmunesysteminovariancancer |